SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
Of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2004
INTERLEUKIN GENETICS, INC.
--------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23413 94-3123681
-------- --------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
135 Beaver Street, Waltham, MA 02452
-------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code: (781) 398-0700
--------------
Item 5. Other Events.
------- -------------
On March 16, 2004, Interleukin Genetics, Inc. publicly disseminated a press
release announcing that it had achieved a pre-defined milestone in its
Nutrigenomics Collaboration with Alticor and as a result of this
achievement had received a $2,000,000 capital contribution from Alticor.
The information contained in the press release is incorporated herein by
reference and filed as Exhibit 99.1 hereto
Item 7. Financial Statements and Exhibits.
------- ----------------------------------
(c) Exhibit
99.1 Press Release dated March 16, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERLEUKIN GENETICS, INC.
--------------------------
(Registrant)
Date: March 16, 2004 /s/ Fenel M. Eloi
------------------------------------
Fenel M. Eloi, Chief Operating Officer,
Chief Financial Officer, Treasurer and
Secretary and Treasurer